These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 14630265)

  • 1. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial.
    Wallner K; Merrick G; True L; Sutlief S; Cavanagh W; Butler W
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1297-303. PubMed ID: 14630265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose regions versus likelihood of cure after prostate brachytherapy.
    Wallner K; Merrick G; Sutlief S; True L; Butler W
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):170-4. PubMed ID: 15850918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isotope selection for patients undergoing prostate brachytherapy.
    Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial.
    Wallner K; Merrick G; True L; Sherertz T; Sutlief S; Cavanagh W; Butler W
    Radiother Oncol; 2005 Jun; 75(3):307-10. PubMed ID: 16086912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
    Stock RG; Stone NN
    Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma.
    Dattoli M; Wallner K; Sorace R; Koval J; Cash J; Acosta R; Brown C; Etheridge J; Binder M; Brunelle R; Kirwan N; Sanchez S; Stein D; Wasserman S
    Int J Radiat Oncol Biol Phys; 1996 Jul; 35(5):875-9. PubMed ID: 8751395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.
    Herstein A; Wallner K; Merrick G; Mitsuyama H; Armstrong J; True L; Cavanagh W; Butler W
    Cancer J; 2005; 11(5):385-9. PubMed ID: 16259869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd 103 plus beam radiation therapy.
    Sherertz T; Wallner K; Merrick G; Cavanagh W; Butler W; Reed D; True L
    Cancer J; 2004; 10(5):301-6. PubMed ID: 15530259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen spikes after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials.
    Merrick GS; Wallner KE; Galbreath RW; Butler WM; Fiano R; Orio PF; Adamovich E
    Brachytherapy; 2015; 14(5):677-85. PubMed ID: 26051802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
    Merrick GS; Butler WM; Galbreath RW; Lief JH
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment margins predict biochemical outcomes after prostate brachytherapy.
    Choi S; Wallner KE; Merrick GS; Cavanagh W; Butler WM
    Cancer J; 2004; 10(3):175-80. PubMed ID: 15285927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications.
    Stock RG; Stone NN; Cesaretti JA
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):448-53. PubMed ID: 12738319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
    Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
    Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation.
    Lee LN; Stock RG; Stone NN
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):444-52. PubMed ID: 11872291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer.
    Prestidge BR; Hoak DC; Grimm PD; Ragde H; Cavanagh W; Blasko JC
    Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):31-9. PubMed ID: 9054874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.